cisplatin + cyclophosphamide + epirubicin + fluorouracil + paclitaxel

This is a multi-agent chemotherapy regimen composed of five cytotoxic drugs: cisplatin, cyclophosphamide, epirubicin, fluorouracil (5-FU), and paclitaxel. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells: - Cisplatin is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. - Cyclophosphamide is an alkylating agent that interferes with DNA replication by adding alkyl groups to DNA. - Epirubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, preventing proper DNA replication and repair. - Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting RNA and DNA synthesis. - Paclitaxel is a taxane that stabilizes microtubules and prevents their disassembly during cell division. This combination targets multiple pathways essential for cancer cell survival and proliferation. Such regimens are typically used in the treatment of advanced or high-risk cancers where multi-drug therapy may improve response rates compared to single agents. The specific combination listed here does not correspond to a widely recognized named protocol but represents an intensive approach sometimes considered in clinical trials or for aggressive malignancies.